Jupiter Neurosciences (NASDAQ:JUNS – Get Free Report) and Sandoz Group (OTCMKTS:SDZNY – Get Free Report) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.
Earnings & Valuation
This table compares Jupiter Neurosciences and Sandoz Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jupiter Neurosciences | $40,448.00 | 217.16 | -$8.65 million | ($0.27) | -0.90 |
| Sandoz Group | $11.09 billion | 3.20 | $914.00 million | N/A | N/A |
Profitability
This table compares Jupiter Neurosciences and Sandoz Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jupiter Neurosciences | N/A | -1,314.62% | -228.63% |
| Sandoz Group | N/A | N/A | N/A |
Analyst Ratings
This is a breakdown of current ratings and recommmendations for Jupiter Neurosciences and Sandoz Group, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jupiter Neurosciences | 1 | 0 | 0 | 0 | 1.00 |
| Sandoz Group | 0 | 1 | 0 | 3 | 3.50 |
Risk & Volatility
Jupiter Neurosciences has a beta of 1.71, meaning that its share price is 71% more volatile than the S&P 500. Comparatively, Sandoz Group has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500.
Institutional and Insider Ownership
0.1% of Sandoz Group shares are owned by institutional investors. 50.8% of Jupiter Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Sandoz Group beats Jupiter Neurosciences on 7 of the 10 factors compared between the two stocks.
About Jupiter Neurosciences
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.
About Sandoz Group
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology, as well as bone disease. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland.
Receive News & Ratings for Jupiter Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jupiter Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.
